Sequencing of Therapies for Early-Stage Breast Cancer

Video

An expert perspective on the evolving role of neoadjuvant therapy and how sequencing methods for the treatment of early-stage breast cancer have been affected during the COVID-19 pandemic.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Related Content
Plant-Based Diet/Exercise Tied to Weight Loss in HR+ Breast Cancer

Plant-Based Diet/Exercise Tied to Weight Loss in HR+ Breast Cancer

Roman Fabbricatore
June 13th 2024
Article

Patients with hormone receptor-positive breast cancer experienced weight loss when given a plant-based diet plus exercise.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study

39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study

Lucia Castro Hernandez;Zaineb Shatawi;Joshua P. Parreco;Lucy M. De La Cruz
June 9th 2024
Article
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer

Sarah Donahue, MPH, NP
January 15th 2024
Podcast

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.

T-DXd Boosts PFS Vs Chemo in HR+, HER2-Low Metastatic Breast Cancer

Chris Ryan
June 2nd 2024
Article

Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.

Data also show a longer median time to deterioration for patients in the inavolisib arm in phase 3 INAVO120 trial.

Inavolisib Combo Reduces Time to Subsequent Treatment in Breast Cancer

Silas Inman
June 2nd 2024
Article

Data also show a longer median time to deterioration for patients in the inavolisib arm in phase 3 INAVO120 trial.